2023
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction
Avula V, Sharma G, Kosiborod M, Vaduganathan M, Neilan T, Lopez T, Dent S, Baldassarre L, Scherrer-Crosbie M, Barac A, Liu J, Deswal A, Khadke S, Yang E, Ky B, Lenihan D, Nohria A, Dani S, Ganatra S. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction. JACC Heart Failure 2023, 12: 67-78. PMID: 37897456, DOI: 10.1016/j.jchf.2023.08.026.Peer-Reviewed Original ResearchConceptsCancer therapy-related cardiac dysfunctionSGLT2 inhibitor useGuideline-directed medical therapyHeart failureInhibitor useSGLT2 inhibitorsMedical therapyCardiac dysfunctionAntineoplastic therapyAtrial fibrillation/flutterType 2 diabetes mellitusAcute HF exacerbationCox proportional HRsAcute kidney injuryRenal replacement therapyRetrospective cohort analysisIschemic heart diseaseRisk of cardiomyopathyAggregate patient dataTriNetX Research NetworkProportional HRsCause hospitalizationCause mortalityHF exacerbationKidney injury
2022
Advances in Multimodality Imaging in Cardio-Oncology JACC State-of-the-Art Review
Baldassarre LA, Ganatra S, Lopez-Mattei J, Yang EH, Zaha VG, Wong TC, Ayoub C, DeCara JM, Dent S, Deswal A, Ghosh AK, Henry M, Khemka A, Leja M, Rudski L, Villarraga HR, Liu JE, Barac A, Scherrer-Crosbie M, Councils A. Advances in Multimodality Imaging in Cardio-Oncology JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2022, 80: 1560-1578. PMID: 36229093, DOI: 10.1016/j.jacc.2022.08.743.Peer-Reviewed Original ResearchConceptsCardio-oncology patientsAdverse cardiovascular effectsLong-term survivorsPopulation of patientsCardiovascular complicationsPregnant patientsCardiovascular effectsCardiac massAntineoplastic therapyJACC StateVascular toxicityPatientsMultimodality imagingCancerImagingNumerous advancesReviewComplicationsAtherosclerosisTherapyPopulationDiseaseSurvivorsDiagnosisCardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS)
Lopez-Mattei J, Yang EH, Baldassarre LA, Agha A, Blankstein R, Choi AD, Chen MY, Meyersohn N, Daly R, Slim A, Rochitte C, Blaha M, Whelton S, Dzaye O, Dent S, Milgrom S, Ky B, Iliescu C, Mamas MA, Ferencik M. Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS). Journal Of Cardiovascular Computed Tomography 2022, 17: 66-83. PMID: 36216699, DOI: 10.1016/j.jcct.2022.09.002.Peer-Reviewed Original ResearchConceptsCardio-OncologyCardiac CTCardio-oncology patientsExpert consensus statementCardiovascular Computed TomographyExpert consensus documentConsensus statementComputed tomographyCurrent evidenceConsensus documentMultimodality imagingPractice recommendationsRadiation oncologyCCT applicationMultidisciplinary collaborationOncologyTomographic imagingImagingPatientsLimited guidanceCardiacCliniciansCardiologyCTCare
2021
Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience
Batra A, Patel B, Addison D, Baldassarre LA, Desai N, Weintraub N, Deswal A, Hussain Z, Brown SA, Ganatra S, Agarwala V, Parikh PM, Fradley M, Ghosh A, Guha A. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart 2021, 8: e001849. PMID: 34952868, PMCID: PMC8710909, DOI: 10.1136/openhrt-2021-001849.Peer-Reviewed Original ResearchConceptsCardiovascular adverse eventsAdverse Event Reporting SystemCombination therapyAntimicrotubular agentsVinca alkaloidsAdverse eventsDrug Administration Adverse Event Reporting SystemRoutine cardiovascular assessmentCardiovascular safety profilePolytomous logistic regressionEvent Reporting SystemAgent therapyCombination chemotherapyHeart failureRegistry experienceSafety profileCardiovascular assessmentHigh burdenInhibitor combinationsChemotherapeutic agentsTaxanesTherapyLogistic regressionMonotherapyReporting system
2020
Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils
Baldassarre LA, Yang EH, Cheng RK, DeCara JM, Dent S, Liu JE, Rudski LG, Strom JB, Thavendiranathan P, Barac A, Zaha VG, Bucciarelli-Ducci C, Ellahham S, Deswal A, Lenneman C, Villarraga HR, Blaes AH, Ismail-Khan R, Ky B, Leja MJ, Scherrer-Crosbie M. Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. Journal Of The National Cancer Institute 2020, 113: 513-522. PMID: 33179744, PMCID: PMC7717327, DOI: 10.1093/jnci/djaa177.Peer-Reviewed Original ResearchConceptsCardio-OncologyCardiovascular careCOVID-19Cardio-oncology patientsPrior cancer historyExpert consensus statementCoronavirus disease 2019 (COVID-19) pandemicExpert consensus documentRisk of infectionDisease 2019 pandemicCardiotoxicity surveillanceCardiovascular complicationsPericardial involvementLethal complicationCardiac dysfunctionOncology patientsRisk of exposureCancer historyCancer patientsCardiovascular diseaseConsensus statementAmerican CollegeCardiovascular treatmentConsensus documentPatientsOpportunities for improved cardiovascular disease prevention in oncology patients.
Bravo-Jaimes K, Marcellon R, Varanitskaya L, Kim PY, Iliescu C, Gilchrist SC, Baldassarre LA, Manisty C, Ghosh AK, Guha A, Lopez-Mattei JC. Opportunities for improved cardiovascular disease prevention in oncology patients. Current Opinion In Cardiology 2020, 35: 531-537. PMID: 32649353, DOI: 10.1097/hco.0000000000000767.Peer-Reviewed Original ResearchConceptsCardiovascular disease preventionCancer patientsDisease preventionCardiovascular disease prevention guidelinesCardiac risk factor modificationCancer treatmentCardiometabolic disease managementDisease prevention guidelinesCardiovascular risk factorsHigh cardiovascular riskRisk factor modificationAdverse cardiovascular outcomesRisk of cardiotoxicityOngoing clinical trialsNonpharmacologic therapiesCardiovascular eventsCardiovascular outcomesCardiovascular riskOncology patientsCancer survivorsPrevention guidelinesAdverse outcomesFactor modificationCardiorespiratory fitnessRisk factors